Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.182    
  

 
 

PUBLIC HEALTH SERVICE    
    
    BIOLOGICAL MATERIALS LICENSE AGREEMENT    
  

        This Agreement is entered into between the Public Health Service ("PHS"), through the Office of Technology Transfer, National Institutes of Health, Box OTT,
Bethesda, Maryland 20892, U.S.A. and MedImmune Inc. ("LICENSEE"), a corporation of Delaware, having an office at 35 West Watkins Mill Road, Gaithersburg, Maryland. 

        1.    Definitions: 

	a.
	"Materials"
means the following biological materials: murine hybridoma cell lines designated as #1153, #1142, #1129, #1121, #1243, #1261-25, #1236-4,
#1228-28, #1224-1, #1219-22, #1175-40, #1113-44, and #1105-1 developed in the laboratory of Drs. Brian Murphy and Robert
Chanock.

	b.
	"Licensed
Products" means monoclonal antibodies against respiratory syncytial virus.

	c.
	"Net
Sales" means the total gross receipts by LICENSEE for sales, leasing, and renting of Licensed Products, whether invoiced or not, less returns and allowances actually granted,
rebates to the extent actually allowed, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in
amounts customary in the trade. No deductions shall be made for commissions paid to individuals, whether they be with independent sales agencies or regularly employed by LICENSEE, or for the cost of
collections. 

        2.    LICENSEE
wishes to obtain a license from PHS to use the Materials provided under this Agreement in its commercial research or product development and marketing
activities. LICENSEE represents that it has the facilities, personnel and expertise to use the Materials for commercial purposes and agrees to expend reasonable efforts and resources to develop the
Materials for commercial use and/or commercial research. 

        3.    PHS
hereby grants to LICENSEE a worldwide, non-exclusive license to make, have made and use the Materials and to make, have made, use and sell Licensed
Products. 

        4.    PHS
agrees to provide LICENSEE with samples of the Materials, excluding progeny, subclones and derivatives thereof, ("Supplied Materials"), as available, and at
reasonable cost to replace the Supplied Materials, as available, in the event of their unintentional destruction. 

        5.    In
consideration of the grant in Paragraph 3 above, LICENSEE hereby agrees to make the following payments to PHS: 

	a.
	Within
30 days of its execution of this Agreement, a noncreditable, nonrefundable license issue royalty of (CONFIDENTIAL TREATMENT REQUESTED);

	b.
	A
nonrefundable minimum annual royalty of (CONFIDENTIAL TREATMENT REQUESTED) which shall be due and payable on January 1, 1995 and on January 1 of each calendar
thereafter, (CONFIDENTIAL TREATMENT REQUESTED) of which shall be full creditable against earned royalties due under paragraph 5 (c) below in any year, provided, however, that no royalty
payment under paragraph 5 (c) shall be reduced by more than (CONFIDENTIAL TREATMENT REQUESTED);

	c.
	An
earned royalty of (CONFIDENTIAL TREATMENT REQUESTED) of Net Sales for Licensed Products that contain Materials in whole or in part and (CONFIDENTIAL TREATMENT REQUESTED) on all
other Licensed Products, which shall be due and payable within sixty days of the end of each calendar year. 

All
payments required under this Agreement shall be in U.S. Dollars, net of all non-U.S. taxes, and shall be made by check or bank draft drawn on a United States bank and made payable to
"NIH/Patent Licensing". All such payments shall be sent to the following address: NIH, P.O. Box 360120, Pittsburgh, Pennsylvania, 15251-6120. 

        6.    LICENSEE
agrees to make written reports to PHS within sixty (60) days after the end of each calendar year. This report shall state the number, description, and
aggregate Net Sales of Licensed Products sold, leased or rented by LICENSEE and the resulting calculation pursuant to Paragraph 5 of payment due. LICENSEE shall submit each such report along
with payment due PHS for the calendar year covered by the report to PHS at the address listed in Paragraph 5 above and shall also send a copy
of the report to PHS at the Mailing Address for Notices indicated on the Signature Page of this Agreement. 

        7.    LICENSEE
agrees to supply the laboratory of Drs. Murphy and Chanock (PHS) at no charge reasonable quantities, solely determined by LICENSEE, of Materials and Licensed
Products that LICENSEE offers for sale or otherwise makes available for public use. 

        8.    This
Agreement shall become effective on the date when the last party to sign has executed this Agreement and shall terminate twenty (20) years from this effective
date, unless previously terminated under the terms of Paragraphs 15 or 16 below. 

        9.    LICENSEE
agrees to retain control over the Materials, and not to distribute them to third parties without the prior written consent of PHS except as provided in
Paragraph 3, except for use in making Licensed Products by LICENSEE. 

        10.  LICENSEE
agrees that this Agreement does not preclude PHS from distributing the Materials to third parties for research or commercial purposes. 

        11.  By
this Agreement, PHS grants no patent rights expressly or by implication to any anticipated or pending PHS patent applications or issued patents. 

        12.  NO
WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE MATERIALS OR LICENSED PRODUCTS MAY BE EXPLOITED WITHOUT
INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. LICENSEE accepts license rights to the Materials and Licensed Products "as is", and PHS does not offer any guarantee of any kind. 

        13.  LICENSEE
agrees to indemnify and hold harmless the United States government from any third party claims, costs, damages or losses that may arise from or through
LICENSEE's use of the Materials or Licensed Products. LICENSEE further agrees that it will not by its action bring the United States government into any lawsuit involving the Materials or Licensed
Products. PHS shall provide LICENSEE written notification of any claims as soon as practicable after PHS has knowledge of such claims. 

        14.  LICENSEE
agrees in its use of any PHS-supplied materials to comply with all applicable statutes, regulations and guidelines, including Public Health Service
and PHS regulations and guidelines. LICENSEE agrees not to use the Materials for research involving human subjects or clinical trials in the United States without complying with 21 CFR Part 50
and 45 CFR Part 46. LICENSEE agrees not
to use the Materials for research involving human subjects or clinical trials outside of the United States without notifying PHS, in writing, of such research or trials and complying with the
applicable regulations of the appropriate national control authorities. Written notification to PHS of research involving human subjects or clinical trials outside of the United States shall be given
no later than sixty (60) days prior to commencement of such research or trials. 

        15.  LICENSEE
may terminate this Agreement upon sixty (60) days written notice to PHS. 

        16.  PHS
may terminate this Agreement if LICENSEE is in default in the performance of any material obligation under this Agreement, and if the default has not been remedied
within ninety (90) days after the date of written notice by PHS of such default. 

        17.  Upon
termination of this Agreement, LICENSEE agrees to return all Materials to PHS, or provide PHS with certification of their destruction. 

        18.  Within
ninety (90) days of termination of this Agreement, LICENSEE agrees to submit a final report to PHS, and to submit payment of any royalties due. 

        19.  LICENSEE
is encouraged to publish the results of its research projects using the Materials or Licensed Products. In all oral presentations or written publications
concerning the Materials or Licensed Products, LICENSEE will acknowledge the contribution of Drs. Murphy and Chanock and the PHS agency supplying the Materials, unless requested otherwise by PHS or
Drs. Murphy and Chanock. 

        20.  This
Agreement shall be construed in accordance with the laws of the United States as interpreted and applied by the Federal courts in the District of Columbia. 

        21.  This
Agreement constitutes the entire understanding of PHS and LICENSEE and supersedes all prior agreements and understandings with respect to the Materials. 

        22.  The
provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any
controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. 

        23.  Paragraphs
12, 13 and 19 of this Agreement shall survive termination of this Agreement. 

 
 

PHS BIOLOGICAL MATERIALS LICNESE AGREEMENT    
    
    SIGNATURE PAGE    
  

        In Witness Whereof, the parties have executed this agreement on the dates set forth below. Any communication or notice to be given shall be forwarded to the
respective addresses listed below. 

	FOR PHS:
	

/s/  BARBARA M. MCGAREY J.D.      
 Barbara M. McGarey J.D.	

August 24, 1994
 Date

Deputy
Director, Office of Technology Transfer

National Institutes of Health 

	Mailing Address for Notices:	Office of Technology Transfer

National Institutes of Health

Box OTT

Bethesda, Maryland 20892

FOR
LICENSEE (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of LICENSEE made or referred to in this Agreement are truthful and
accurate.) 

	

/s/  WAYNE T. HOCKMEYER      
 Wayne T. Hockmeyer	

June 30, 1994
 Date

Chairman
and Chief Executive Officer 

	Mailing Address for Notices:	MedImmune, Inc.

35 W. Watkins Mill Road

Gaithersburg, MD 20878

QuickLinks

Exhibit 10.182

PUBLIC HEALTH SERVICE BIOLOGICAL MATERIALS LICENSE AGREEMENT

PHS BIOLOGICAL MATERIALS LICNESE AGREEMENT SIGNATURE PAGEQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.183    
  

 
 

LICENSE AGREEMENT    
  

        This agreement ("Agreement") is entered into by and between the University of Iowa Research Foundation ("UIRF"), located at 214 Technology Innovation Center, Iowa
City, IA 52242 and MedImmune, Inc., ("MedImmune") having a place of business at 35 West Watkins Mill Road, Gaithersburg, Maryland 20878. 

        WHEREAS,
UIRF is owner by assignment from Prof. Mark F. Stinski, of U.S. Patent Nos. 5,168,062 and 5,385,839, issued December 1, 1992, and January 31, 1995 respectively,
titled "Transfer Vectors and Microorganisms containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter-Regulatory DNA Sequence" (no foreign filings have been undertaken by the UIRF); 

        WHEREAS,
MedImmune desires a non-exclusive license to the above United States patents for their use in the production of proteins; 

        WHEREAS,
UIRF wishes to grant such a license in accordance with the terms of this Agreement. 

        NOW
THEREFORE, the parties agree as follows: 

 
 

ARTICLE I—DEFINITIONS    
  

        1.1  Licensed
Patents shall mean U.S. Patent Nos. 5,168,062 and 5,385,839, issued December 1, 1992, and January 31, 1995 respectively, titled "Transfer Vectors
and Microorganisms containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter-Regulatory DNA Sequence", by Prof. Mark F. Stinski, or any U.S. patents issuing thereon, including any
continuations, continuations-in-part, divisions, reissues, reexaminations and extensions thereof and patents corresponding thereto. 

        1.2  Licensed
Products shall mean and include any and all biological materials and products and processes the making, having made, using, selling or importing of which would,
but for this Agreement, constitute an infringement of one or more Valid Claims of the Licensed Patents. 

        1.3  Valid
Claim shall mean any claim in an unexpired patent included within Licensed Patents which claim has not been disclaimed or held invalid or unenforceable by an
unappealed or unappealable decision of a court. 

        1.4  Licensed
Field shall mean the use of the Licensed Patents and the making, having made, using, selling or importing of the Licensed Products in the  production of proteins by cell culture. Licensed Field
specifically excludes any use of the Licensed Patents or use and/or sale of Licensed Products for
gene therapy applications and genetic immunization or DNA-based vaccines. 

        1.5  Licensed
Territory shall mean any country in which the making, having made, using, selling or importing of Licensed Products would, but for the license granted in this
Agreement, infringe one or more Valid Claims of the Licensed Patents. 

        1.6  Net
Sales shall mean the gross amount received by MedImmune and/or its Affiliates from the sales of Licensed Products within the Licensed Field in the Licensed Territory
to third party customers less: 

        a)    normal
and customary rebates, cash and trade discounts actually allowed; 

        b)    credits
allowed for returned or damaged goods; 

        c)    insurance
and transportation costs; and 

        d)    sales,
excise, value added, import and export taxes, and any tariffs and duties paid with respect to sales. 

1

 

        On
sales between MedImmune and its Affiliates for resale, the royalty shall be paid on the resale. 

        1.7  Effective
Date shall mean December 1, 1997. 

        1.8  Yearly
Accounting Period shall mean an annual period beginning on January 1 and ending on December 31 of the same year. 

        1.9  Earned
Royalties shall mean royalties paid or payable by MedImmune and/or its Affiliates to UIRF as determined with respect to Net Sales. 

        1.10 Affiliate
shall mean any corporation owning or controlling, directly or indirectly, at least forty-nine (49%) of the stock normally entitled to vote for
election of directors of a party. 

        1.11 For
purposes of this Agreement, Partner shall mean any third party company or legal entity which is not controlled by or under common control with MedImmune, with which
MedImmune has a joint venture or collaboration or marketing/distribution or such other formal arrangement providing the third party company the right to co-manufacture,
co-develop, co-promote or co-market Licensed Products in the Licensed Field in conjunction with MedImmune. 

 
 

ARTICLE II—THE GRANT    
  

        2.1  UIRF
hereby grants to MedImmune and its Affiliates, subject to the terms and conditions hereof, a non-exclusive license under Licensed Patents to make, have
made, use, import, sell, offer to sell, have sold the Licensed Products within the Licensed Field in the Licensed Territory. 

        2.2  To
ensure that any Partner (as defined in paragraph 1.11) has the appropriate enabling rights to make, have made, use, sell and import the Licensed Products in
the Licensed Field, MedImmune shall
direct its Partner to enter into a direct license with the UIRF for the Licensed Patents in the Licensed Field as outlined below: 

        (i)    MedImmune
agrees to notify such Partner within thirty (30) days of the execution of any formal agreement between MedImmune and such Partner, and 

        (ii)  MedImmune
shall notify the Partner that the Partner will need to obtain a separate license to the Licensed Patents for the Licensed Field directly from the UIRF for the
Partner's use, manufacture, sale or import of any Licensed Products and that the license terms of Exhibit A are valid only if the UIRF/Partner license is executed on or before
December 1, 1998, and 

        (iii)  MedImmune
shall promptly send copies to UIRF of all such notifications sent to such Partners, specifying the Licensed Products that are the subject of the agreement
between MedImmune and the Partner. 

Since
(a) the UIRF has granted a number of non-exclusive licenses to the Licensed Patents and (b) there exist several inter-relationships between UIRF's licensees and
licensees' affiliates, the Partners of MedImmune may already have enabling licenses for the Licensed Patents within the Licensed Field. Additionally, since UIRF will get delayed notification of the
nature of the relationship between MedImmune and its Partner, UIRF cannot be the party determining whether any of MedImmune's Partners have such enabling licenses already. The UIRF will not
intentionally collect any double payments; however, all payments made to UIRF are non-refundable and UIRF shall not be held responsible for any double payments that are made by MedImmune
and/or its Partners. 

2

 
 
 

ARTICLE III—PAYMENTS, REPORTS, RECORD-KEEPING    
  

        3.1  In
consideration of the rights granted to MedImmune pursuant to Article 2.1 of this Agreement, MedImmune agrees to make the following payments to the UIRF: 

        (a)  A
non-refundable license fee in the sum of (CONFIDENTIAL TREATMENT REQUESTED) upon execution of this Agreement. 

        (b)  Earned
Royalties in an amount equal to (CONFIDENTIAL TREATMENT REQUESTED) of the Net Sales of Licensed Products to be paid on a semi-annual basis. MedImmune
agrees to submit to UIRF within sixty (60) days after December 31 and June 30, reports setting forth for the preceding six (6) month period the Net Sales of Licensed
Products and royalty due thereon and with each such royalty report to pay the amount of royalty due. 

In
the event that a Licensed Product is sold in the Licensed Field in combination with therapeutically active product which is not a Licensed Product for a single price, Net Sales from such sales for
purposes of calculating the amounts due under Section 3.3 above shall be calculated by multiplying the Net Sales of that combination by the fraction A/(A + B), where A is the
gross selling price of the same quantity of Licensed Product sold separately by MedImmune in the normal course of business and B is the gross selling price of the other product. In the event that no
such separate sales are made by MedImmune, Net Sales for royalty determination shall be as reasonably allocated between such Licensed Product and such other product, based upon their relative
importance and proprietary protection as agreed to by the parties. 

        (c)  On
each anniversary of the Effective Date of this Agreement a license maintenance fee of (CONFIDENTIAL TREATMENT REQUESTED) until the expiration of the Licensed Patents. 

        3.2  In
the event that MedImmune becomes obligated at any time or from time to time during the term of this Agreement to pay royalties to any third party for the practice of
any method or use of any composition of matter covered by any claim of the Licensed Patents or for the sale of any Licensed Products, MedImmune's royalty obligation to the UIRF shall be reduced by an
amount equal to its royalty obligation to such third party; provided, however, that MedImmune's royalty obligation shall not be reduced by more than fifty percent (50%) for any one calendar quarter. 

        3.3  MedImmune's
obligation to make payments hereunder shall be suspended during any period of time that MedImmune is enjoined, or reasonably believes it may be enjoined,
from exercising any of its rights hereunder with respect to the Licensed Patents or any Licensed Products. Upon resolution of any such matter, MedImmune shall promptly pay to UIRF all amounts
previously withheld with respect to such matter, less (i) any reduction which may be applicable pursuant to paragraph above, and (ii) expenses incurred in the resolution thereof. 

        3.4  MedImmune
shall report, not any less frequently than annually, on its efforts and progress made toward commercialization of any products involving Licensed Patents. 

        3.5  MedImmune
shall keep accurate and correct records of Licensed Products made, used or sold under this Agreement. Such records shall be retained for at least three
(3) years following a given reporting period. UIRF is hereby granted by MedImmune the right, upon reasonable written notice to MedImmune and appropriately bound by confidentiality, to retain an
independent certified public accountant reasonably acceptable to MedImmune to audit MedImmune's records solely to verify sales
of the Licensed Products. UIRF may designate an agent for purposes of this verification and this verification shall be upon reasonable notice to MedImmune. 

        3.6  All
payments due hereunder shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the
United States as reported in The Wall Street Journal on the last working day of each royalty period. Such payments shall be without deduction of exchange, collection or other charges. 

3

 

        3.7  Late
payments shall be subject to an interest charge of one and one-half percent (1.5%) per month. 

 
 

ARTICLE IV—TERM AND TERMINATION    
  

        4.1  Unless
terminated earlier in accordance with this Agreement, the term of the license granted hereunder shall expire upon the expiration of the last to expire of the
Licensed Patents. 

        4.2  In
the event MedImmune fails to make payments due hereunder, UIRF shall have the right to terminate this Agreement upon forty-five (45) days written
notice, unless MedImmune makes such payments plus interest within the forty-five (45) day notice period. 

        4.3  In
the event that MedImmune shall become insolvent, shall make an assignment for the benefit of its creditors, or shall have a petition in bankruptcy filed for or
against it and such petition shall not have been discharged within ninety (90) days, UIRF may, at its option, terminate this license upon thirty (30) days written notice. 

        4.4  MedImmune
shall have the right to terminate this Agreement at any time by written notice to UIRF to that effect. 

        4.5  MedImmune
shall have the right during a period of six (6) months following the effective date of such termination to sell or otherwise dispose of the Licensed
Products existing at the time of such termination, and shall make a final report and payment of all royalties related thereto within sixty
(60) days following the end of such period or the date of the final disposition of such inventory, whichever first occurs. 

 
 

ARTICLE V—ASSIGNMENT    
  

        5.1  This
Agreement may be assigned by MedImmune as part of a transfer of all, or substantially all, of the business to which this Agreement relates. This Agreement shall be
binding upon and inure to the benefit of successors in interest and assigns of MedImmune. MedImmune agrees to inform UIRF of such transfer promptly. 

 
 

ARTICLE VI—REPRESENTATIONS: LIMITATIONS    
  

        6.1  Nothing
in this Agreement shall be construed as: 

        (a)  A
warranty or representation by UIRF as to the validity or scope of any Licensed Patent; or 

        (b)  A
warranty or representation that anything made, used, sold or otherwise commercialized under the license granted in this Agreement is or will be free from infringement
of patents owned by third parties; or 

        (c)  Conferring
a right to use in advertising, publicity or otherwise the name of the University of Iowa ("UI") or UIRF, unless UIRF has specifically approved the same in
writing. 

        6.2  UIRF
expressly disclaims any and all implied or express warranties and makes no express or implied warranties of merchantability or fitness for any particular purpose of
the Licensed Patent, Biological Materials or Licensed Processes or Licensed Products contemplated by this Agreement. 

 
 

ARTICLE VII—GENERAL    
  

        7.1  MedImmune
shall not distribute or resell the Licensed Products to others except in accordance with the rights granted under Article II of this Agreement.
MedImmune agrees to comply with all applicable laws and regulations. 

4

 

        7.2  UIRF
shall have the responsibility for the prosecution, filing and maintenance of all Licensed Patents, including the conduct of all interference, opposition, nullity
and revocation proceedings, as well as responsibility for all fees and costs associated therewith. 

        7.3  A
party shall inform the other of any suspected infringement of any Licensed Patents in the Licensed Field by a third party. UIRF shall have the right but not the
obligation at its expense to initiate any proceeding relating to any infringement by a third party of any Licensed Patents in the Licensed Field. 

        7.4  UIRF
shall have no obligation to defend any action for infringement brought against MedImmune by a third party. 

        7.5  The
relationship between UIRF and MedImmune shall be that of independent contractors. UIRF and MedImmune shall have no other relationship other than as independent
contracting parties. UIRF shall have no power to bind or obligate MedImmune in any manner, except as is expressly set forth in this Agreement. 

        7.6  MedImmune
shall indemnify and hold harmless UIRF and UI and their employees and officers and their respective successors, heirs and assigns, from any action, claim or
liability, including, without limitation, liability for death, personal injury, or property damages arising directly or indirectly from MedImmune's possession, distribution or other use of Licensed
Products under this Agreement and/or from MedImmune's publication or distribution of test reports, data and other information relating to Licensed Products, provided: 

        (a)  MedImmune
shall not be obligated under this paragraph if it is shown by evidence acceptable in a court of law having jurisdiction over the subject matter and meeting the
appropriate degree of proof for such action, that the injury was the result of the negligence, wrongful actions or willful misconduct of any employee of UIRF or UI; and 

        (b)  MedImmune
shall have no obligation under this paragraph unless: 

        (i)    UIRF
or UI gives MedImmune prompt written notice of any claim or lawsuit or other action for which it seeks to be indemnified under this License Agreement; and 

        (ii)  UI
or UIRF fully cooperate with MedImmune and its agents in defense of the claims or lawsuit or other action. 

        (c)  Only in those instances where action is brought for SOLELY MedImmune products, MedImmune shall be granted full authority and control over the
defense, including settlement, against such claim or lawsuit or other action.

        7.7  If
any provision of this Agreement is ultimately held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions
shall not in any way be affected or impaired thereby. 

        7.8  Any
delay in enforcing a party's rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of a party's right to
the future enforcement of its rights under this Agreement, except in the event of written and signed waiver. 

        7.9  The
captions herein are solely for convenience of reference and shall not affect the construction or interpretation of this Agreement. 

 
 

ARTICLE VIII—NOTICES; APPLICABLE LAW    
  

        8.1  Any
notice, report or payment provided for in this Agreement shall be deemed sufficiently given when sent by facsimile or regular, certified or registered mail addressed
to the party for whom 

5

 

intended at the following addresses, or to such address as either party may hereafter designate in writing to the other: 

For
UIRF: University of Iowa Research Foundation, Attn: Ms. Usha R. Balakrishnan, Associate Director

214 Technology Innovation Center, Iowa City, IA 52242-5000

Phone: 319-335-4546/Fax: 319-335-4489 

For
MedImmune: MedImmune, Inc., Attn: President

35 West Watkins Mill Road, Gaithersburg, Maryland 20878

        with a copy to: Michael Richman, Vice President, Business Development 

        8.2  This
agreement shall be construed, interpreted, and applied in accordance with the laws of the State of Iowa. 

 
 

ARTICLE IX—INTEGRATION    
  

        9.1  This
Agreement contains the entire agreement of the parties with respect to the subject matter hereof, all prior understandings relating thereto being merged herein.
This Agreement cannot be changed or terminated orally, but only in writing and if signed by both parties. This Agreement shall be binding on the heirs, successors, and assigns of the parties hereto. 

	AGREED to:	 	 	 	 
	

LICENSOR	
 	

LICENSEE
	University of Iowa Research Foundation	 	MedImmune, Inc.
	

By:	
 	

/s/  W. BRUCE WHEATON, PH.D.      
	
 	

By:	
 	

/s/  DAVID M. MOTT      

	

Date: December 9, 1997	
 	

Date: December 12, 1997
	

Name: W. Bruce Wheaton, Ph.D.

Title: Executive Director	
 	

Name: David M. Mott

Title: President

6

  

 
 

EXHIBIT A    
  

LICENSE
TERMS FOR CMV PROMOTER PATENTS

For protein production field

U.S. Patent Nos. 5,168,062 and 5,385,839, by Mark Stinski

License available from the University of Iowa Research Foundation (UIRF) 

	1. Licensed Patents	 	U.S. Patent No. 5,168,062 titled "Transfer Vectors and Microorganisms containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter-Regulatory DNA Sequence", by Prof. Mark F. Stinski, issued December 1, 1992,
its continuations and divisionals (no international filings have been undertaken by the UIRF); and U.S. Patent No. 5,385,839, titled "Transfer Vectors and Microorganisms containing Human Cytomegalovirus (HCMV) Immediate-Early Promoter Regulatory
DNA Sequence" by Prof. Mark F. Stinski, issued January 31, 1995.
	
2. License	
 	

Non-exclusive, for licensed field of use
	
3. Licensed field	
 	
PRODUCTION OF PROTEINS
	
4. License fee	
 	
(CONFIDENTIAL TREATMENT REQUESTED), payable upon execution of the License Agreement
	
5. Royalties	
 	

(CONFIDENTIAL TREATMENT REQUESTED) on Sales, payable semi-annually
	
6. Maintenance fees	
 	
(CONFIDENTIAL TREATMENT REQUESTED), payable annually on each anniversary date of the License Agreement.

Note:
The above terms are valid only if the license agreement is executed on or before December 1, 1998. 

Contact
person for licensing interest for this or any other field of use license: 

Ms. Usha
R. Balakrishnan

Associate Director

University of Iowa Research Foundation

214 Technology Innovation Center

Iowa City, Iowa 52242

Phone: 319-335-4546

Fax: 319-335-4489 

7

QuickLinks

Exhibit 10.183

LICENSE AGREEMENT

ARTICLE I—DEFINITIONS

ARTICLE II—THE GRANT

ARTICLE III—PAYMENTS, REPORTS, RECORD-KEEPING

ARTICLE IV—TERM AND TERMINATION

ARTICLE V—ASSIGNMENT

ARTICLE VI—REPRESENTATIONS: LIMITATIONS

ARTICLE VII—GENERAL

ARTICLE VIII—NOTICES; APPLICABLE LAW

ARTICLE IX—INTEGRATION

EXHIBIT A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]